Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study

Cover Page

Cite item

Full Text

Abstract

Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) in the Russian patient population.

Materials and methods. This retrospective study included 231 patients (157 males and 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination and treatment at Moscow City Hospital named after S.S. Yudin and Moscow Center for Rehabilitation Treatment.

Results. The median follow-up was 16.6 months (13.38-18.61). The effectiveness of therapy was evaluated in all patients included in the study. Objective response (complete regression + partial regression) was achieved in 45 (19.5%) patients. Disease control (objective response + stabilization) was reported in 186 (80.5%) subjects. Median of overall survival in patients with metastatic RCC was 15.62 months (95% confidence interval [CI] 12.89-17.75): in the 1st line group, 13.18 months (95% CI 11.21-17.75), and in the 2nd and subsequent lines group, 16.72 months (95% CI 13.41-20.19). Grade 1-2 immune-mediated adverse events were reported in 81.8% (n=189) of patients, of which 97 (78.9%) received 1st line immunotherapy and 92 (85.2%) received 2nd and subsequent lines.

Conclusion. RCC immunotherapy in the Russian population is associated with high rates of objective response and disease control in the first line of treatment (19.5 and 80.5%, respectively). This treatment method is typically associated with a small number of grade 3-4 immune-mediated adverse events (3.03% according to our data), which indicates an acceptable safety profile and is comparable with the data from foreign studies.

About the authors

Marina A. Lyadova

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"; Novokuznetsk State Institute for Postgraduate Medical Education – branch of the Russian Medical Academy of Continuous Professional Education

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0002-9558-5579
SPIN-code: 8220-2854

Cand. Sci. (Med.)

Russian Federation, Moscow; Novokuznetsk

Denis S. Fedorinov

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"; Russian Medical Academy of Continuous Professional Education

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0001-5516-7367
SPIN-code: 1079-8460

Oncologist

Russian Federation, Moscow; Moscow

Tatiana A. Nersesova

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Author for correspondence.
Email: dr.nersesova@gmail.com
ORCID iD: 0000-0002-7853-0349

Oncologist

Russian Federation, Moscow

Yana V. Gridneva

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5Moscow Center for Rehabilitation Treatment

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0002-9015-2002
SPIN-code: 4189-6387

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Maria I. Volkova

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"; Russian Medical Academy of Continuous Professional Education

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0001-7754-6624

D. Sci. (Med.)

Russian Federation, Moscow; Moscow

Konstantin V. Lyadov

Sechenov First Moscow State Medical University (Sechenov University); Moscow Center for Rehabilitation Treatment

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0001-5468-5074

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow; Moscow

Evgeniya S. Kuzmina

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Email: dr.nersesova@gmail.com
ORCID iD: 0009-0007-2856-5176
SPIN-code: 9668-5733

oncologist

Russian Federation, Moscow

Tatyana G. Antonova

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Email: dr.nersesova@gmail.com
ORCID iD: 0009-0007-6646-7454

oncologist

Russian Federation, Moscow

Ilya A. Pokataev

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0001-9864-3837
SPIN-code: 7338-9428

D. Sci. (Med.)

Russian Federation, Moscow

Vsevolod N. Galkin

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Email: vsgalkin@gmail.com
ORCID iD: 0000-0002-6619-6179

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Irina V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Email: dr.nersesova@gmail.com
ORCID iD: 0000-0002-0995-1801

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow

References

  1. Cancer Genome Atlas Research Network; Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New Engl J Med. 2016;374(2):135-45. doi: 10.1056/NEJMoa1505917
  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi: 10.3322/caac.21708
  3. Fay AP, McKay RR, Lin X, et al. Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. J Glob Oncol. 2018;4:1-14. doi: 10.1200/JGO.17.00119z
  4. Zhuang TZ, Case K, Olsen TA, et al. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. Cancers (Basel). 2022;14(12):2867. doi: 10.3390/cancers14122867
  5. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87. doi: 10.14740/wjon1279
  6. Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. ПА. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023 [Zlokachestvennyie novoobrazovaniia v Rossii v 2022 godu (zabolevaiemost i smertnost). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. PA. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023 (in Russian)].
  7. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132-6.
  8. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nature reviews. Immunology. 2018;18(3):153-67. doi: 10.1038/nri.2017.108
  9. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358
  10. Topalian S, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. AMA Oncol. 2019;5(10):1411-20. doi: 10.1001/jamaoncol.2019.2187
  11. McDermott DF, Motzer RJ, Atkins MB, et al. Longterm overall survival with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. Abstract (4507) presented at the Annual Meeting of the American Society of Clinical Oncology; June 3–7, 2016; Chicago, IL.
  12. Motzer RJ, Escudier B, George S,et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156-67. doi: 10.1002/cncr.33033
  13. Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085-97. doi: 10.1002/cncr.34180
  14. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-90. doi: 10.1056/NEJMoa1712126
  15. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi: 10.1136/esmoopen-2020-001079
  16. Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol. 2019;37(23):2008-16. doi: 10.1200/JCO.18.02218
  17. Emamekhoo H, Olsen MR, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2022;128(5):966-74. doi: 10.1002/cncr.34016
  18. Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405-15. doi: 10.1016/S1470-2045(18)30081-0
  19. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-27. doi: 10.1056/NEJMoa1816714
  20. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563-73. doi: 10.1016/S1470-2045(20)30436-8
  21. P Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses. Ann Oncol. 2020;31(4):S558-9. doi: 10.1016/j.annonc.2020.08.782
  22. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-68. doi: 10.1056/NEJMra1703481
  23. Abou Alaiwi S, Xie W, Nassar AH, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000144. doi: 10.1136/jitc-2019-000144
  24. Ornstein MC, Garcia JA. Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. Kidney Cancer. 2017;1(2):133-41. doi: 10.3233/KCA-170017
  25. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi: 10.1186/s40425-019-0805-8

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Survival by the line of therapy.

Download (99KB)
Indexing metadata
3. Fig. 2. Survival from the date of diagnosis by the line of therapy.

Download (100KB)
Indexing metadata
4. Fig. 3. PFS by the line of therapy.

Download (64KB)
Indexing metadata

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).